The UK and US have concluded a landmark commercial pact that will maintain zero tariffs on British pharmaceutical products going into the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise funding on medicines through the National Health Service (NHS). This pledge guarantees that duties on these key exports will remain at zero for a timeframe of the next three years.
This deal is in response to previous warnings to significantly raise import taxes on branded drug products, with increases floated up to double the cost.
"This agreement between the Britain strengthens the worldwide climate for cutting-edge drugs and brings long-overdue fairness to U.S.–U.K. medicine commerce," a release noted.
Commercial Importance
Pharmaceuticals represent one of the Britain's most significant export categories to the US, which is clearly the primary destination for leading British pharmaceutical firms.
Statistics reveal that in the 12 months to the end of the third quarter, the UK exported medicines worth billions to the US. This value accounted for nearly one-fifth of British export trade in that period.
"This guarantee safeguards jobs, increases investment and paves the way for the UK to emerge as a worldwide center for medical research," a minister commented.
Key British Pledges
The pact involves several specific changes from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a aim to raise overall NHS spending on drugs from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The sum manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. Previously, repayments were more than 20%.
Industry Background
This agreement takes place against a ongoing row between the drug companies and the UK government over spending levels and NHS adoption.
The disagreement were heightened by claims that American customers were paying several times more for the equivalent treatments than people in the other developed nations.
Recently, several significant manufacturing plans in the UK have been delayed or abandoned, while major investments have been directed toward American operations.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
